Project Grant R01CA301614
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$646K
Federal Agency
National Cancer Institute
Awardee
Emory University (S352L5PJLMP8)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
This federal Project Grant award under the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $606,697 to the Augusta University Research Institute, Inc. (doing business as Georgia Health Sciences) to conduct research on suppressing the co-chaperone UNC45A as a novel immunotherapeutic target for treating triple-negative breast cancer (TNBC).
The key products and services to be delivered include:
Characterizing how suppressing UNC45A in TNBC tumors reprograms...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $701,408 to The General Hospital Corporation (Massachusetts General Hospital) to conduct research aimed at elucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system (CNS) metastases from breast cancer. The project involves several ongoing Phase II clinical trials exploring the use of newly...
This federal Project Grant award provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to develop a novel therapeutic approach for overcoming radiation resistance in triple negative breast cancer (TNBC). The $512,582 award supports research to investigate the mechanism by which vascular endothelial growth factor (VEGF) signaling through neuropilin-2 (NRP2) contributes to radiation resistance, and to test whether targeted inhibition of...
This $649,679 Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) will fund research conducted by The Institute For Cancer Research to investigate a novel strategy for enhancing cancer immunotherapy responsiveness. The project aims to determine if targeting the RNA/DNA helicase DHX9 can induce "viral mimicry" in small cell lung cancer cells, triggering an antiviral immune response and improving the efficacy of immune checkpoint blockade...
The National Cancer Institute (NCI) awarded a 5-year, $709,554 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Emory University to advance the understanding of how a novel neoadjuvant therapy impacts the immune system in patients with solid tumors, using refractory melanoma as a model. The key objectives are to:
Gain insights on how blocking the Semaphorin 4D (SEMA4D) protein, when combined with immune checkpoint blockade, affects the induction and infiltration of...
This $603,347 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Albert Einstein College of Medicine in the Bronx, NY funds research to develop targeted therapies for T-cell malignancies. Specifically, the grant supports efforts to:
Define the transition state structure of the enzyme SAMHD1, which can inhibit the efficacy of the PNP inhibitor forodesine in treating certain T-cell cancers.
Discover SAMHD1 inhibitors that, when combined...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $517,732 in funding to the University of Colorado-Denver to conduct research on mechanisms of endocrine therapy and radiation synergism in decreasing brain metastases from breast cancer. The 5-year project aims to:
Examine how endocrine therapies and radiation therapy work synergistically to promote anti-tumor immune responses and block brain metastasis progression by upregulating...
This $622,329 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) is funding research at Virginia Commonwealth University (VCU) to develop an inhibitor called PDZ1i that can prevent metastasis and improve the efficacy of chemotherapy for triple-negative breast cancer (TNBC). The key research objectives include: 1) Formulating the PDZ1i inhibitor for clinical use and characterizing its immunomodulatory effects in suppressing...
This $577,818 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to develop new therapeutic combinations to boost the "abscopal effect" and improve clinical outcomes for patients with advanced cancers. The award supports research at Mayo Clinic to investigate the role of the immune checkpoint molecule B7-H3 in mediating tumor immune evasion, with the goal of overcoming resistance to radiotherapy. The...
Emory University was awarded a $586,875 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 1, 2023 to August 31, 2026 to elucidate and exploit SAMHD1 for breast cancer therapy. Through this funding, Emory University researchers will investigate medical solutions for breast cancer by exploring the role of the SAMHD1 protein and developing new therapeutic approaches for...